Table of Contents - WOC 2012

IS-ONC-FR 89 (3)
Adjuvant Therapy in Uveal Melanoma.
Singh Arun (1)
1. Cole Eye Institute
The increasing ability to identify a group of high-risk patients with primary uveal
melanoma should allow the more rationale use of systemic therapy as an
adjuvant to primary therapy aimed at preventing any micro-metastases from
developing into clinical disease.
IS-ONC-FR 89 (4)
Targeted Therapy for Uveal Melanoma
El Filali Mariam (1)
1. Leiden University Medical Center
A challenge in cancer treatment is selective and potent delivery of drugs to
tumor cells. Since the discovery of mutations in the GNAQ/GNA11 gene in
uveal melanomas (UM), which constitutively activate the MAPK pathway,
interfering with this pathway has become of interest to those who want to cure
UM. Tyrosine kinase inhibitors, such as Dasatinib, are interesting due to their
ability to target multiple kinases and may be used for UM. Individual tumor
targeting based on tumor-specific mutations, may provide treatment options
for metastases and reduce adverse side effects.
IS-ONC-FR 89 (5)
Molecular Basis of Targeted Therapy in Uveal Melanoma
Woodman Scott (1)
1. MD Anderson Cancer Center
The focus of this presentation is to review our current state of knowledge of the
molecular underpinnings of uveal melanoma. Data showing the results of broad
genetic analysis of uveal melanoma tumors and cell lines will be revealed.
Pre-clinical studies showing the nature of activating mutations in GNAQ and
GNA11 and the effects of targeting downstream mediators of mutant GNAQ
and GNA11 will be presented. Clinical trials that capitalize on the molecular
underpinnings of uveal melanoma will also be presented.
IS-ONC-FR 89 (6)
New Approaches for Retinoblastoma
Murray Timothy (1)
1. Bascom Palmer Eye Institute
Major advances in retinoblastoma treatment have occurred over the last
several years. The paradigm shift has moved the focus from systemic
therapy to focal treatment. An evolving treatment is the use of intra-arterial
chemotherapy coupled with focal transpupillary laser tumor ablation to achieve
tumor control without requiring systemic treatment. Current strategies have
employed intra-arterial Melphalan alone, or in combination with Topotecan,
delivered in a micro-pulsed fashion to the ophthalmic artery. Early evaluation
has suggested excellent short-term local tumor control but concerns remain
regarding long-term tumor control, potential for metastatic disease, and serious
vascular driven ocular complications.
New Technology in Ophthalmology Part 1
Fri 17 Feb 10:30 - 12:00 Conference Room B2
IS-TEC-FR 90 (1)
The Coming Nanotechnology Revolution
Montemagno Carlo (1)
1. University of Cincinnati
Abstract not available
WOC2012 Abstract Book
IS-TEC-FR 90 (2)
Gold Nanoparticles: An Efficient Vector for Corneal Gene Therapy
Mohan Rajiv (1)
1. University of Missouri-Columbia
We examined polyethyleneimine-conjugated gold nanoparticles (PEI2-GNP)
for corneal gene therapy using in vivo rabbit disease models using transfection
solutions of different nitrogen and phosphate molar ratios. Nanoparticles
distribution, toxicity and gene transfer efficiency to the cornea were analyzed
by transmission and scanning electron microscopy, neutron activation, and
clinical and histological examinations. The PEI2-GNP showed significant gene
delivery into normal and diseased rabbit corneas, in vivo with low toxicity.
Tested PEI2-GNPs have potential for developing non-viral gene therapy
approaches for corneal diseases.
IS-TEC-FR 90 (3)
Current Status of Stem Cell Therapy in Ophthalmology
Xie Ting (1)
1. Stowers Institute for Medical Research
Stem Cells have been advocated to treat a variety of degenerative diseases. In
addition to embryonic stem cells and induced pluripotent stem cells, multipotent
adult stem cells have unique advantages for therapeutic application due to their
tissue-specific differentiation potential. In my presentation, I will discuss our
recent progress and potential challenges in using multipotent retinal stem cells
to treat retinal degeneration diseases. I will also discuss different approaches
for generation of patient-specific retinal cells for therapeutic application and
studying disease mechanisms.
IS-TEC-FR 90 (4)
Confocal Microscopy of the Subepithelial Nerve Plexus - A Monitor
for Degenerative Nerve Disease
Guthoff Rudolf F. (1)
1. University of Rostock, Eye Department
The corneal subepithelial nerve plexus is surface parallel orientated and
related to Bowman›s membrane. This allows visualization and quantification
of nerve fibre density and pattern (branching, tortuosity). For the first time
non-invasive in-vivo evaluation of trigeminal nerve anatomy and pathology
is possible. It will be demonstrated that confocal nerve fibre images strictly
correlate with various stages of diabetic neuropathy, so confocal nerve fibre
analysis may pave the way for a more comprehensive management for
diabetic and other neuropathic patients.
IS-TEC-FR 90 (5)
24-hour Monitoring of Intraocular Pressure
Michelson Georg (1,2)
1. Interdisciplinary Center of Ophthalmic Preventive Medicine and Imagin
2. Department of Ophthalmology, Friedrich-Alexander University
A continuous monitoring of intraocular pressure would open new perspectives,
not only in the management of glaucoma, but also in basic research for
mechanisms of glaucoma. The purpose is to describe current projects
developing devices for continuous monitoring of intraocular pressure Several
systems are published or under research: (1) fluid-filled catheter, (2) silicone
intraocular lens, (3) intraocular pressure measurement at the choroid surface,
(4) sensing contact lens, (5) telematic assisted self-tonometry, (6) foldable
intraocular lens with IOP-sensor (under research).
119